On Friday, Century Therapeutics Inc (NASDAQ: IPSC) opened higher 6.29% from the last session, before settling in for the closing price of $1.43. Price fluctuations for IPSC have ranged from $1.14 to $5.51 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -14.25% over the last five years. Company’s average yearly earnings per share was noted 30.50% at the time writing. With a float of $34.38 million, this company’s outstanding shares have now reached $84.76 million.
The firm has a total of 165 workers. Let’s measure their productivity. In terms of profitability, gross margin is -404.17%, operating margin of -4925.59%, and the pretax margin is -4869.53%.
Century Therapeutics Inc (IPSC) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Century Therapeutics Inc is 59.56%, while institutional ownership is 31.01%. The most recent insider transaction that took place on Nov 04 ’24, was worth 1,267. In this transaction Chief Operations Officer of this company sold 1,033 shares at a rate of $1.23, taking the stock ownership to the 135,130 shares. Before that another transaction happened on Nov 04 ’24, when Company’s SVP Finance & Operations sold 283 for $1.23, making the entire transaction worth $347. This insider now owns 317,147 shares in total.
Century Therapeutics Inc (IPSC) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 30.50% per share during the next fiscal year.
Century Therapeutics Inc (NASDAQ: IPSC) Trading Performance Indicators
Check out the current performance indicators for Century Therapeutics Inc (IPSC). In the past quarter, the stock posted a quick ratio of 10.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 51.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.86, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.76 in one year’s time.
Technical Analysis of Century Therapeutics Inc (IPSC)
Analysing the last 5-days average volume posted by the [Century Therapeutics Inc, IPSC], we can find that recorded value of 0.64 million was better than the volume posted last year of 0.29 million. As of the previous 9 days, the stock’s Stochastic %D was 41.80%. Additionally, its Average True Range was 0.14.
During the past 100 days, Century Therapeutics Inc’s (IPSC) raw stochastic average was set at 20.43%, which indicates a significant decrease from 50.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 103.46% in the past 14 days, which was higher than the 84.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4404, while its 200-day Moving Average is $2.5203. Now, the first resistance to watch is $1.5900. This is followed by the second major resistance level at $1.6600. The third major resistance level sits at $1.7400. If the price goes on to break the first support level at $1.4400, it is likely to go to the next support level at $1.3600. Now, if the price goes above the second support level, the third support stands at $1.2900.
Century Therapeutics Inc (NASDAQ: IPSC) Key Stats
There are currently 85,029K shares outstanding in the company with a market cap of 137.37 million. Presently, the company’s annual sales total 2,240 K according to its annual income of -136,670 K. Last quarter, the company’s sales amounted to 790 K and its income totaled -31,230 K.
